First Trust Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

First Trust Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,857	Closed	-$945K	–	2501
2022 Q4	$945K	Buy	20,857 +14,302	+218%	+$926K	﹤0.01%	1976
2022 Q3	$458K	Buy	+6,555	New	+$485K	﹤0.01%	2233
2022 Q2	–	Sell	-4,335	Closed	-$356K	–	2642
2022 Q1	$356K	Sell	4,335 -46,405	-91%	-$4.75M	﹤0.01%	2339
2021 Q4	$7.44M	Buy	+50,740	New	+$7.88M	0.01%	1184
2021 Q3	–	Sell	-4,029	Closed	-$651K	–	2669
2021 Q2	$651K	Sell	4,029 -26,331	-87%	-$4.23M	﹤0.01%	2190
2021 Q1	$5.2M	Buy	30,360 +13,332	+78%	+$2.64M	0.01%	1216
2020 Q4	$3.74M	Buy	17,028 +8,429	+98%	+$1.82M	0.01%	1244
2020 Q3	$1.43M	Buy	+8,599	New	+$1.18M	﹤0.01%	1560
2020 Q2	–	Sell	-25,853	Closed	-$1.99M	–	2477
2020 Q1	$1.99M	Buy	+25,853	New	+$2.32M	﹤0.01%	1271
2019 Q4	–	Sell	-25,535	Closed	-$1.99M	–	2477
2019 Q3	$1.99M	Buy	+25,535	New	+$2.4M	﹤0.01%	1538

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

First Trust Advisors's MRTX Position: Q1 2023 in Review

First Trust Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 20,857 shares — an estimated $945K sold.

First Trust Advisors first reported a position in MRTX in Q3 2019 and held it in 10 quarters. The position peaked at $7.44M in Q4 2021. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

First Trust Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
First Trust Advisors sold 20,857 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $945K.
First Trust Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
First Trust Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $7.44M in Q4 2021.
221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on First Trust Advisors's 13F filing for Q1 2023, filed 15 May 2023.